Dataset Information

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8⁺ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.

ABSTRACT: To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138⁺ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8⁺ CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA_72-80 (YLMFLLRKI), and BCMA_54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activati

SUBMITTER: Bae J

PROVIDER: S-EPMC6728221 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8⁺ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8⁺ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.